ArticleBioinformation2026
Comparative evaluation of diode laser fibrotomy versus intralesional dexamethasone plus hyaluronidase for moderate oral submucous fibrosis.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral submucous fibrosis (OSMF) represents a chronic, progressive, potentially malignant disorder lacking consensus on optimal management strategies for moderate clinical stages. Therefore, it is of interest to compare diode laser fibrotomy (Group A) versus intralesional dexamethasone sodium phosphate plus hyaluronidase (Group B) in 30 patients with moderate (Group II-III) OSMF. Mouth opening and cheek flexibility measurements at baseline, 1, 3 and 6 months revealed statistically significant intragroup improvements in both groups (p < 0.001). Intergroup analysis demonstrated significantly greater functional gains with laser fibrotomy compared to intralesional therapy (p < 0.001), highlighting superior clinical efficacy. Thus, we show OSMF management by establishing diode laser fibrotomy as a minimally invasive, highly effective treatment option for moderate disease stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.